CA2755109A1 - Sparc angiogenic domain and methods of use - Google Patents

Sparc angiogenic domain and methods of use Download PDF

Info

Publication number
CA2755109A1
CA2755109A1 CA2755109A CA2755109A CA2755109A1 CA 2755109 A1 CA2755109 A1 CA 2755109A1 CA 2755109 A CA2755109 A CA 2755109A CA 2755109 A CA2755109 A CA 2755109A CA 2755109 A1 CA2755109 A1 CA 2755109A1
Authority
CA
Canada
Prior art keywords
tumors
seq
sparc
polypeptide
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2755109A
Other languages
English (en)
French (fr)
Inventor
Vuong Trieu
Daniel Knauer
Neil Desai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abraxis Bioscience LLC
Original Assignee
Abraxis Bioscience LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abraxis Bioscience LLC filed Critical Abraxis Bioscience LLC
Publication of CA2755109A1 publication Critical patent/CA2755109A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2755109A 2009-03-11 2010-03-11 Sparc angiogenic domain and methods of use Abandoned CA2755109A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15932209P 2009-03-11 2009-03-11
US61/159,322 2009-03-11
PCT/US2010/027041 WO2010105097A2 (en) 2009-03-11 2010-03-11 Sparc angiogenic domain and methods of use

Publications (1)

Publication Number Publication Date
CA2755109A1 true CA2755109A1 (en) 2010-09-16

Family

ID=42729116

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2755109A Abandoned CA2755109A1 (en) 2009-03-11 2010-03-11 Sparc angiogenic domain and methods of use

Country Status (13)

Country Link
US (2) US20120087910A1 (cg-RX-API-DMAC7.html)
EP (1) EP2405932A4 (cg-RX-API-DMAC7.html)
JP (1) JP2012520081A (cg-RX-API-DMAC7.html)
KR (2) KR20130043242A (cg-RX-API-DMAC7.html)
CN (2) CN102482334A (cg-RX-API-DMAC7.html)
AU (1) AU2010224031B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI1009457A2 (cg-RX-API-DMAC7.html)
CA (1) CA2755109A1 (cg-RX-API-DMAC7.html)
IL (2) IL215089A0 (cg-RX-API-DMAC7.html)
MX (1) MX2011009478A (cg-RX-API-DMAC7.html)
NZ (1) NZ595528A (cg-RX-API-DMAC7.html)
WO (1) WO2010105097A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201107415B (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2544704A4 (en) * 2010-03-11 2013-08-28 Abraxis Bioscience Llc SPARC ANGIOGENIC DOMAIN AND METHODS OF USE
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
CN120361186B (zh) * 2025-04-15 2025-12-30 北京大学口腔医学院 一种促进血管生成和组织再生的药物组合物及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001266787A1 (en) * 2000-06-07 2002-01-08 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
WO2006112930A2 (en) * 2005-02-18 2006-10-26 Abraxis Bioscience, Inc. Q3 sparc deletion mutant and uses thereof
WO2008000079A1 (en) * 2006-06-26 2008-01-03 The University Of British Columbia Secreted protein acidic and rich in cysteine (sparc) as chemotherapeutic sensitizers
CN101678078B (zh) * 2007-04-13 2014-12-10 阿布拉西斯生物科学公司 Sparc及其使用方法

Also Published As

Publication number Publication date
EP2405932A2 (en) 2012-01-18
US20120087910A1 (en) 2012-04-12
MX2011009478A (es) 2011-11-18
IL215089A0 (en) 2011-11-30
CN103724417A (zh) 2014-04-16
WO2010105097A3 (en) 2010-11-04
US20140094416A1 (en) 2014-04-03
KR20130043242A (ko) 2013-04-29
BRPI1009457A2 (pt) 2016-03-01
WO2010105097A8 (en) 2011-05-26
KR20110139256A (ko) 2011-12-28
AU2010224031B2 (en) 2013-05-02
JP2012520081A (ja) 2012-09-06
AU2010224031A1 (en) 2011-10-06
ZA201107415B (en) 2012-06-27
AU2010224031A2 (en) 2011-10-20
WO2010105097A2 (en) 2010-09-16
EP2405932A4 (en) 2012-08-22
CN102482334A (zh) 2012-05-30
NZ595528A (en) 2013-10-25
IL228795A0 (en) 2013-12-31

Similar Documents

Publication Publication Date Title
JP7838929B2 (ja) Xbp1、cd138およびcs1ペプチド、該ペプチドを含有する薬学的組成物、ならびにかかるペプチドおよび組成物を使用する方法
US20140094416A1 (en) Sparc angiogenic domain and methods of use
JP5622885B2 (ja) 細胞の除去または破壊を必要とする腫瘍および他の状態の処置に有効なペプチド
JP5496220B2 (ja) アルブミン結合ペプチド介在性の疾患標的化
US20130196929A1 (en) Secreted protein acidic and rich in cysteine (sparc) as chemotherapeutic sensitizers
CN102245632A (zh) Muc-1胞质结构域肽作为癌症的抑制剂
JP2011149961A (ja) 骨髄およびリンパ系細胞癌の診断および処置
JP2025164866A (ja) 乳がんを処置するためのペプチドワクチンおよびペムブロリズマブ
EP2630963A1 (en) SPARC angiogenic domain and methods of use
AU2013211470A1 (en) Sparc angiogenic domain and methods of use
JP5666110B2 (ja) 高機能化hvj−eの開発
HK1194403A (en) Sparc angiogenic domain and methods of use
HK1167664A (en) Sparc angiogenic domain and methods of use

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20150629